Therapy Optimization in Multiple Sclerosis (MS) (TOP MS)

Teva Pharmaceuticals

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

Study type: Observational

Funder types: Industry

Identifiers

NCT00819000

PM032

Details and patient eligibility

About

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Enrollment: 2,878 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, 18 years of age or older, with a diagnosis of MS.
• Being treated with Glatiramer Acetate (GA) or (IFN)-β
• Receiving therapy from a participating Specialty Pharmacy

Exclusion criteria

• Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
• Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
• Unlikely to be able to participate for the full two years of the study

Trial design

2,878 participants in 1 patient group

Treated MS Subjects

Description:

Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies

Treatment:

Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b